Back to mobile site

Zymeworks (ZYME) Reiterated at Market Outperform by Citizens as Theravance Biopharma Acquisition Closed

September 29, 2026 5:28 AM EDT Send to a Friend
Citizens analyst Reni Benjamin reiterated a Market Outperform rating and $32.00 price target on Zymeworks (NASDAQ: ZYME).The analyst commented, "We ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login